Is Wellbutrin (Bupropion) Safe with Ketamine?

If you're already taking Wellbutrin (bupropion) and considering at-home ketamine therapy, the question patients raise most often is about seizure risk. It's a fair question because Wellbutrin's labeling carries a seizure-threshold warning, and ketamine's reputation as an anesthetic creates an intuitive (and wrong) sense that the two together must compound risk. The honest answer, when you look at the published evidence and at what the FDA itself has approved, is that the combination at standard doses is safe.

Why patients worry about this combination

Two specific concerns drive the question. First, bupropion's package insert mentions seizure risk, and that warning has been internalized by both prescribers and patients. Second, ketamine is best known to most people as a dissociative anesthetic, which sounds like the kind of medication that should never go near another drug that touches seizure threshold. Both concerns are fair to voice. Both turn out to be much smaller than they appear once you separate dose form, dose level, and the actual neurochemistry from the surface intuition.

Bupropion is an NDRI, meaning it inhibits the reuptake of norepinephrine and dopamine. It does not act on serotonin (which is why it doesn't cause the sexual side effects or weight gain associated with SSRIs and is often added to or substituted for them). Its modest effect on seizure threshold is dose-dependent and form-dependent: peak plasma concentrations matter more than total daily dose, which is why the immediate-release (IR) formulation carries the strongest labeling and why the extended-release (XL) formulation is the dominant prescription today.

Ketamine works on glutamate, not norepinephrine, dopamine, or serotonin. Specifically, it antagonizes the NMDA glutamate receptor and triggers a downstream cascade involving AMPA receptor activation and BDNF release. Its effect on seizure threshold has been studied directly and it's the opposite of what most people assume: at therapeutic doses ketamine has anticonvulsant properties.

What the seizure-threshold evidence actually shows

The clearest answer to the seizure question comes from a 2024 systematic review by Shehata and colleagues in Heliyon (PMID 38293492). The authors set out specifically to ask whether ketamine is pro-epileptic or anti-epileptic, and they reviewed 30 studies. The result was lopsided: 26 studies supported ketamine's antiepileptic properties; only 4 suggested pro-epileptic effects. Their conclusion was direct: "Existing research does not conclude definitively that ketamine is a pro-epileptic agent."

The reported pro-epileptic events occurred mostly in procedural-sedation contexts where ketamine was used as monotherapy at anesthetic doses, not at the much lower antidepressant doses we use at home. Ketamine is in fact used in clinical practice as a treatment for refractory status epilepticus, which would be impossible if it were a pro-convulsant at therapeutic doses.

What this means for the bupropion question: the combination doesn't stack two seizure-threshold-lowering drugs on top of each other. It pairs a modest threshold-lowering drug (bupropion at standard doses) with a drug whose net effect on seizure threshold at our doses is neutral to anticonvulsant.

The FDA's own precedent: Auvelity

In August 2022 the FDA approved a fixed-dose combination drug called Auvelity for major depression. Auvelity combines dextromethorphan, an NMDA receptor antagonist, with bupropion, the same drug we're discussing here. The bupropion in Auvelity is there partly to inhibit the metabolism of dextromethorphan (extending its NMDA-antagonist action), and the combination was approved as a daily oral antidepressant.

This matters because the FDA reviewed and approved a combination of bupropion plus an NMDA antagonist for depression treatment. That's structurally what we're asking about with ketamine. If combining bupropion with an NMDA antagonist were dangerous from a seizure-threshold or pharmacodynamic standpoint, the FDA would not have approved Auvelity. The agency's risk assessment is direct evidence that this class of combination has an acceptable safety profile in depression treatment.

What the broader evidence shows on bupropion plus ketamine outcomes

For the antidepressant-effectiveness question (will Wellbutrin help, hurt, or do nothing to the ketamine response?), the picture mirrors what we see with SSRIs: no meaningful interaction in either direction.

The most recent and largest direct study is Curran and colleagues' 2026 analysis in the Journal of Clinical Psychiatry (DOI 10.4088/JCP.25br16294), which looked at 332 patients on IV ketamine or intranasal esketamine grouped by their concurrent antidepressant class. Bupropion patients were grouped with "other antidepressants," and the analysis found no differential outcomes by concurrent antidepressant. Patients on bupropion responded to ketamine on the same trajectory as patients on no antidepressant.

The Veraart and colleagues 2021 systematic review in International Journal of Neuropsychopharmacology (PMID 34170315), which catalogued meaningful drug interactions with ketamine, explicitly excluded the bupropion combination from analysis along with SSRIs and SNRIs. The reason is the same one we cited on the Zoloft page: the safety and additive antidepressant effect of ketamine added to "regular antidepressants" (their phrase, includes bupropion) "has already been demonstrated irrefutably." When systematic-review authors describe a clinical question as settled, that's the citation you want.

The largest real-world dataset is Alnefeesi and colleagues' 2022 meta-analysis in the Journal of Psychiatric Research (PMID 35688035), pooling 2,665 treatment-resistant depression patients across 79 studies. Bupropion is among the most common adjunctive antidepressants in treatment-resistant depression specifically, so a substantial portion of these patients were on bupropion when they started ketamine. The pooled response rate was 45% and the pooled remission rate was 30%.

What we do at intake at Tovani

When a patient is on Wellbutrin, our intake process for ketamine is the same as for any patient with a few additional confirmations:

I confirm the bupropion form. Wellbutrin XL (extended release, 150-450 mg once daily) is the most common and the formulation most compatible with the seizure-threshold conversation. Wellbutrin SR (sustained release, twice daily) is fine at standard doses. If you're on immediate-release bupropion specifically, we'll have a brief intake conversation about why and whether a switch to XL makes sense.

I confirm the total daily dose. Doses up to 450 mg/day (the FDA-approved maximum for Wellbutrin XL) are routine. Doses above 450 mg/day are off-label and would prompt a more detailed conversation about why and whether the dose should be revisited.

I review your seizure history. A personal history of seizures, or a family history of epilepsy, doesn't automatically rule you out, but it changes the depth of the intake review. Many of these patients are still candidates; we just confirm specifics first.

I check for other seizure-threshold-lowering medications. Tramadol is the most common one to flag (it lowers seizure threshold and is sometimes prescribed for chronic pain). Theophylline, certain antibiotics, and some antipsychotics are also relevant. The combinations matter more than any single agent.

The high-dose Wellbutrin question (300-450 mg/day)

Some patients with treatment-resistant depression have escalated to higher doses of Wellbutrin XL over time, often because they've tried multiple antidepressants and Wellbutrin at the high end of the range was the one that gave them the most relief. These patients are exactly who at-home ketamine is designed for.

The high dose does not change our verdict. It does change the intake conversation slightly: I confirm you've been stable at the high dose (no recent increases), confirm the indication, and review for compounding factors as above. Many of our most engaged patients are on Wellbutrin XL 300-450 mg/day and do well with concurrent ketamine.

Tapering: a separate conversation

A common question is whether ketamine can be a bridge to coming off Wellbutrin. The answer for some patients is yes and for others no. A meaningful subset of our ketamine patients eventually taper off their existing antidepressant (bupropion included) after stable improvement on ketamine; others do better staying on the combination indefinitely.

The key point: do not stop Wellbutrin to start ketamine. The standard recommendation when starting ketamine is to not change your existing medications at the same time. If tapering is on the table, we discuss it as a planned step after stable improvement on the combination, not as a precondition.

Bottom line

Wellbutrin (bupropion) at standard therapeutic doses is compatible with at-home ketamine therapy. The published evidence on the combination is reassuring across both the seizure-threshold question (a 2024 systematic review found ketamine's profile is anticonvulsant, not pro-convulsant) and the antidepressant-effectiveness question (no differential outcomes by concurrent antidepressant in the most recent large-N analysis). The FDA's own approval of a bupropion plus NMDA-antagonist combination for depression in 2022 is direct precedent for the safety of this class of combination. Patients on Wellbutrin XL at standard doses should expect routine intake; patients on IR formulations or above 450 mg/day get a brief additional conversation, not a different verdict.